Pharmaceutical purchasing
The pharmaceutical laboratory Biolab has acquired the Brazilian operation of Actavis, a company belonging to the Israeli group Teva, which mainly produces drugs that act on the nervous system. The value of the transaction was not disclosed.
"Talks with Teva began in January because the group has been making adjustments to its global operation," says the buyer's CEO, Cleiton de Castro Marques.
With the acquisition, Biolab is looking to grow in the antidepressant segment. Today, half of the company's revenue comes from the cardiology area.
The column found that Actavis earned around R$ 34 million in the country in the 12 months to March.
The company has 150 employees, a factory in Rio and 30 generics in its portfolio.
R$ 1.3 billion was Biolab's revenue in 2017 2,500 are the brand's employees